|
61 |
Therapeutische Endosonografie – Optionen und Fallbeispiele
Hecht, Thomas. - Bonn : Fachinformationszentrum der Bundeswehr, 2025
|
|
|
|
62 |
Towards symbolic XAI — explanation through human understandable logical relationships between features
Schnake, Thomas. - Berlin : Technische Universität Berlin, 2025
|
|
|
|
63 |
Tumor volume change at radiation boost planning to estimate the response to chemoradiotherapy in stage III unresectable NSCLC (TORCH): a multicenter retrospective observational study
Trommer, Simon. - Erlangen : Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 2025
|
|
|
|
64 |
Two approaches to mass closure analysis for carbon-rich aerosol in Metro Manila, Philippines
Betito, Grace. - Augsburg : Universität Augsburg, 2025
|
|
|
|
65 |
Virtual reality-based Harms tangent screen test for strabismus measurement
Wenner, Yaroslava. - Frankfurt am Main : Universitätsbibliothek Johann Christian Senckenberg, 2025
|
|
|
|
66 |
Young unrelated donors confer a survival advantage for patients with myeloid malignancies compared to older siblings
Schetelig, Johannes. - Augsburg : Universität Augsburg, 2025
|
|
|
|
67 |
Young unrelated donors confer a survival advantage for patients with myeloid malignancies compared to older siblings
Schetelig, Johannes. - Aachen : Universitätsbibliothek der RWTH Aachen, 2025
|
|
|
68 |
Preferred Working Time Models and Equal Opportunities in Gynecology and Obstetrics: Results of the Systematic Trinational FARBEN Survey
Enthalten in Geburtshilfe und Frauenheilkunde Bd. 85, 2025, Nr. 03: 311-322
|
|
|
|
69 |
Time for “Code ICH”? Workflow Metrics of Hyperacute Treatments and Outcome in Patients with Intracerebral Haemorrhage
Enthalten in Cerebrovascular diseases Bd. 53, 2025, Nr. 6: 693-702. 10 S.
|
|
|
|
70 |
Palbociclib in Combination with either Aromatase Inhibitors or Fulvestrant for Patients with Advanced HR+/HER2− Breast Cancer in Germany: Final Results of the Phase 2 Multicohort INGE-B Trial
Enthalten in Oncology research and treatment Bd. 48, 2025, Nr. 1-2: 14-25. 11 S.
|
|
Administration
